Pliant Therapeutics (PLRX)

• Market cap: $869M
• 1 day: -2.86%
• 5 days: 5.31%
• 1 month: -4.16%
• 3 months: 6.97%
• 6 months: 18.02%
• Year to date: -20.49%
• 1 year: -1.59%
• 5 years: -32.96%
• 10 years: -32.96%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

Employees: 166

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

81% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 32

47% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 17

6% more funds holding

Funds holding: 143 [Q2] → 151 (+8) [Q3]

4% more capital invested

Capital invested by funds: $694M [Q2] → $725M (+$31.2M) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 5 [Q2] → 5 (+0) [Q3]

2.6% less ownership

Funds ownership: 107.03% [Q2] → 104.43% (-2.6%) [Q3]

74% less call options, than puts

Call options by funds: $1.31M | Put options by funds: $4.99M

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $33 131% upside
• Avg. target: $36 154% upside
• High target: $38 166% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Ed Arce 65% 1-year accuracy 75 / 115 met price target	166% upside $38	Buy Reiterated	8 Nov 2024
HC Wainwright & Co. Ed Arce 65% 1-year accuracy 75 / 115 met price target	166% upside $38	Buy Reiterated	13 Sept 2024
Leerink Partners Faisal Khurshid 57% 1-year accuracy 4 / 7 met price target	131% upside $33	Outperform Assumed	9 Sept 2024